Tuesday, July 31, 2018


1). Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax Injection of The Medicines Company.

2). Beximco Pharmaceuticals Limited has received US Food and Drug Administration (FDA) approval for their Nadolol tablets (20mg, 40mg and 80mg), which are generic equivalent of Bristol-Myers Squibb’s Corgard tablets, for treating hypertension (high blood pressure) and angina pectoris (chest pain).

Periodical revision of faculty norms in APH sought from AICTE to have better pharmacy education

The head of Department of Pharmacy at the government pharmacy college attached to the Madras Medical College in Chennai has written to the All India Council for Technical Education (AICTE) demanding that immediate modification is required in the Approval Process Handbook (APH) 2018-19 by revising the faculty norms and clear all ambiguities in respect of experiences for senior grade professors.

The APH contains rules and regulations for pharmacy education and other technical courses and it is revised every year. But the faculty norms for various educational programmes are not revised yearly.

Prof K Elango says in his letter to the chairman of the AICTE that the faculty norms of teachers in technical institutions including pharmacy colleges were last revised in 2010. As per the norms, experience calculated for senior grade professors includes the candidate’s experiences in industry practice and in research work.

Against this, the head of pharmacy at the college has informed the technical education regulator that it is unfair to take the industry and research experience of a candidate into account while deciding the qualifications for senior grade academic staffs to be appointed as assistant professors or associate professors or professors. He argues that, unlike other technical programmes, pharmacy teaching profession requires experience in teaching various subjects in the pharmaceutical sciences to become a professor. Mere experience in industry cannot be considered as an adequate experience to become a senior grade professor of a professional subject.
“The research or industrial experience cannot be calculated at the academic level or equated them with the academic experience required for an assistant professor / associate professor / professor. Therefore, teaching experience alone should be considered for teaching posts in Pharmacy Institutions. Professorship in senior grade levels is a matter concerned of teaching experiences in various subjects,” says the academic expert.

According to him, the formula given in the APH for calculation of teaching staffs in a degree college is also irrational and it requires revision. As regards the pharmacy course, there are five departments for the graduate course (B Pharm). They are Department of Pharmaceutics, Department of Pharmaceutical Chemistry, Department of Pharmacology, Department of Pharmacognosy and Department of Pharmacy Practice.

“The work load for these five departments is not equal, hence the number of teaching staffs requires for these five subjects differs. So, we cannot accept the formula of the approval process handbook of the AICTE as it is for calculating the staff strength,” said Prof. Elango in an interview with Pharmabiz. His college is affiliated to the MGR Medical University, Chennai and follows the norms of the university.

Another anomaly in the APH, Prof Elango highlights is that the number of in-take for lateral entry for B Pharm is not mentioned in the handbook. He suggests that it should be mentioned as 10 per cent of the total approved in-take of the under graduate programme.

Further, the number of faculty members is also required to be increased. According to AICTE proposal, a pharmacy college requires only one professor for managing all the five departments. But according to Pharmacy Council of India, Prof. Elango says, all the five departments need one professor each. This will help strengthen the pharmacy education system in the country.

PCI also proposes for non-teaching staff such as laboratory technicians, lab assistants, lab attenders, office superintendents, accountants, store keepers, data entry operators, computer operators, clerical staffs, peons, cleaning personnel and gardener. But the APH of the AICTE does not support all these, said Prof. Elango.


Maha Pharmacy Council to kick off online registration for pharmacists from Aug 7

Maharashtra State Pharmacy Council (MSPC) is set to launch online registration system for qualified pharmacists in the state from August 7, 2018 in line with other professional councils in the state. This is in sync with 'Digital India' initiative of the government of India.

This will make the process of registration much faster and eliminate the time-consuming manual work. A number of professional bodies in the state including Maharashtra Nursing Council, Maharashtra Medical Council, Maharashtra Council of Indian Medicine have already introduced online registration system.

All the candidates who have passed out their diploma or degree in pharmacy or Pharm.D. qualification from pharmacy colleges in Maharashtra which are approved by Pharmacy Council of India under Section 12 of Pharmacy Act, 1948 and complying with provisions of Section 32(2) of Pharmacy Act -1948 are required to apply for registration through online system from August 7, said Saili S Masal, registrar of MSPC.

There are 215 Pharmacy Council of India approved diploma colleges and 155 degree colleges in Maharashtra.

The applicants can apply online through the council's website- online.mspcindia.org. The online system features online submission of form, uploading requisite documents, photo, signature and payment of fees by payment gateway. After getting prior appointment generated by the system, applicant has to appear in person at MSPC office to complete verification of their original documents.
With the online system in force, the qualified pharmacists from across the state need to visit MSPC office at the state capital just once to complete verification process. At present, about 1,800 registration processes are done in the council office annually. The work will be made faster and transparent with the launch of the electronic system, said the council registrar, adding that the digitization of registration process is part of the council's ongoing efforts to cater to needs of pharmacists. The council has already launched online refresher course for registered pharmacists to improve their professional know how.

Welcoming the MSPC initiative to make registration process online, Kailash Tandale, president of Maharashtra Registered Pharmacists Association, said “We have long been demanding the online registration of pharmacists in line with other professional councils. It will save travel time and money of applicants as well as make entire registration process transparent.”

He said currently, registration camps conducted by District Chemists & Druggists Associations in the state for fresh pharmacy graduates are found to be charging much more than the fees fixed by MSPC.

For the passed out students to register with MSPC, they have to pay a fees of Rs. 2,650 but they are being charged Rs. 200-300 extra by a number of chemists and druggists associations. Once online registration system kicks off, this will be stopped, he added.

Besides MSPC, a number of state pharmacy councils have already started online registration and renewal of pharmacists. These include pharmacy councils in Gujarat, Telangana, Kerala, Tamil Nadu, Madhya Pradesh, Rajasthan, Karnataka, Andhra Pradesh, and Haryana.


Over 340 drugs to go off the shelves soon

Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).
The Centre is one step closer to banning 343 “irrational” fixed-dose combination (FDC) drugs that were potentially harmful to consumers.
The market size of the banned drugs is estimated to be around Rs 2,000-2,200 crore and will impact the country’s top drugmakers.
Patient advocacy groups say more FDCs, worth Rs 20,000-25,000 crore, are under scanner.
An FDC drug is one that contains two or more active ingredients in a fixed-dosage ratio.
In March 2016, the ministry of health and family welfare had implemented a ban on 349 FDCs based on recommendations of the Chandrakant Kokate committee that found these drug combinations to be irrational and posing health risks.
In December, the Supreme Court referred the matter to the Drug Technical Advisory Board (DTAB) for a fresh review after drugmakers challenged the ban.
The DTAB, in a meeting held in New Delhi on Wednesday, re-inforced the ban on 343 of the 349 drugs.
It, however, felt restricted use could be allowed for six FDCs.
The DTAB would forward its report to the health ministry in the next 7-10 days, said a top government official.
These FDCs roughly contribute to 1.8 per cent of the overall domestic drug market.
The FDC segment is clocking a slower growth rate (4.7 per cent in June) compared to the rest of the domestic drug market (8.6 per cent).
They cover around 6,000 brands mainly from firms like Abbott Healthcare, Mankind Pharma, Wockhardt, Alkem, Lupin, Glenmark, Sun Pharma, Eris Lifesciences and Ipca, among others.
Abbott, perhaps, would take the largest hit. It has an exposure of around Rs 545 crore in these FDCs.
An Abbott spokesperson said the company was awaiting communication from DTAB on the matter.
Abbott is followed by Macleods Pharma (Rs 295 crore) and Mankind Pharma (Rs 134 crore), according to market research firm AIOCD AWACS.
Anticipating the ban, the companies were bracing up.
Pfizer, for instance, has changed the formulation for its popular cough syrup Corex and launched it as Corex T.
Some companies even weeded the products out of their domestic portfolio.
"Only mid-sized firms were selling these drugs, and would be impacted. We had a couple of products in this list and we stopped selling them long time back," the chief of a leading drugmaker said.
S Srinivasan, co-convenor of the All India Drugs Action Network, a patient advocacy group, said they had a public interest litigation in the Supreme Court since 2003 on similar matters.
"These 343 FDCs are only the tip of the iceberg. Over and above the Kokate committee recommendations, there are FDCs that are sold in the country that are potentially harmful to patient health," Srinivasan said.
“The bigger uncertainty would be the additional 944 FDCs that were identified by the Kokate committee as being irrational. Perhaps the DTAB may look at these products now,” Emkay had said in a recent research note.
Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).


Website and Theme launched of IIT Bombay’s Techfest

After bringing about ‘A Zion Revelation’ last year, Techfest wants to continue its space expedition and devises a time-travel portal for the same. It glimpse at primitive technology, intertwined with nature in a sublime manner and also imbibe from futuristic technologies. 
The official website of the 22nd edition is released at 7PM on 29th July. The website is based on the theme – A Timeless Lapse. 

The list of all the events can be found on :

Monday, July 30, 2018

This Indian-American Graduated As A Biomedical Engineer. He's Only 15

15-year-old Tanishq Abraham, graduated from the University of California, Davis with the highest honours of summa cum laude.


  • Tanishq Abraham graduated from the University of California
  • He made device that measures heart rate of burn patients without touching
  • Tanishq Abraham's parents are from Kerala

A 15-year-old Indian-American child prodigy has reached a milestone in his academic journey and is all set to start his doctorate after completing his graduation in biomedical engineering, according to a media report.
Tanishq Abraham, graduated from the University of California, Davis with the highest honours of summa cum laude.
"Of course I feel very happy, very excited, and I'm very proud of my accomplishments," Tanishq was quoted as saying by FOX40.
"He's got a lot of passion and we have to keep up with him, pretty much," said his parents, Taji and Bijou Abraham, hailing from Kerala.
Tanishq has also designed a device that could measure the heart rate of burn patients without touching them.
As for the future, it's back into the lab at Davis for a Ph.D. and eventually medical school. Tanishq has big dreams of finding solutions to problems, the report said.
"Yeah, of course, what everybody likes to say and what I am also interested in is, of course, cancer and developing new treatments for cancer, more effective treatments for cancer," he said.
Tanishq has already been accepted into the University of California, Davis graduate programme where he plans to get his MD in the next four to five years.

Saturday, July 21, 2018

WhatsApp limits forwards to stop violence menace

Source: DNA-21st July,2018

Sun Pharma gets USFDA nod for cancer injection

Sun Pharmaceutical Industries has received approval from the US health regulator for its INFUGEM injection used for the treatment of cancer.
This is the first US Food and Drug Administration (USFDA) approval for a product from the company’s Halol facility after the receipt of Establishment Inspection Report (EIR) in June 2018, Sun Pharma said in a statement today.
The USFDA approval is for INFUGEM injection (gemcitabine in 0.9 per cent sodium chloride injection) 10 mg/mL, for intravenous use in a ready-to-administer bag.
Sun Pharma’s North America CEO, Abhay Gandhi, said, “We’re pleased to add this novel product to our expanding oncology portfolio, as gemcitabine is one of the most commonly used cytotoxics in oncology practices.”
The technology used to formulate INFUGEM eliminates the risks associated with compounding, an extra step in the administration of cytotoxic infusion products, providing improved safety for healthcare professionals and cancer patients, he added.
As per IQVIA, “The addressable market size is approximately $35 million for the 12 months ending March 2018”, Sun Pharma said.
INFUGEM uses a proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in RTA infusion bags.
Sun Pharma shares were trading down by 0.26 per cent at Rs 547.35 on the BSE.


Friday, July 20, 2018

New Arrivals - July,2018


                                                        New Arrival Journals July, 2018

Friday, July 13, 2018

Convert your PG/PhD work into eBooks

Lambert Academic Publishing is an imprint of OmniScriptum
Annually, more than 5,000,000 theses are written worldwide in the research industry. In addition to this are the numerous research notes, articles, and the many creative concepts of professors, universities and institutions.
Enterprises and scientists would be especially interested in these ideas; nevertheless, up to today, most of this work is shelved as a result of high costs.
LAP specializes in the publication of such works and uses commitment and the latest technology in order to make the invaluable work of such researchers available worldwide, quickly and efficiently.
We are an associate member of the American Booksellers Association, the Booksellers Association in the UK and a member of the Börsenverein des Deutschen Buchhandels, the german booksellers association.
Link: https://www.lap-publishing.com/site/who-are-we/11

Saturday, July 07, 2018

‘Higher antibiotic dose helps kill TB’

Neem compound may help in curing cancer - NIPER scientists say it inhibits growth of breast cancer

IITIAN SELECTED FOR LONDON MAYOR'S IE20 BUSINESS PROGRAMME - IIT alumni- Varun Rathi and Anshul Rai's FinTech idea is selected for IE 20 programme by Mayor of London to expand business in the UK

Two IITians started FinTech (financial technology) company in 2012, when the startup boom was yet to happen. What started as a peer to peer (P2P) payment mode has now evolved into a startup called 'Happay' - happy payments - that has digitised corporate financial management in India and made it go paperless.

Anshul Rai and Varun Rathi, both pass out from IIT Kharagpur had quit their jobs at Microsoft and Tata Power, respectively to start Happay. After failing initially, Happay is now certified by Visa and MastserCard, the digital payments and reimbursement system is now used by 4500 corporates including Adani, Aditya Birla group, Oxford University Press, Symphony among others.
The mode helps in generating a plastic card or corporate card for each employee through which monthly reimbursements will be digitally transferred, saving the employee from manually filing papers or submitting bills. Being eco-friendly innovation, it has been selected among the top 20 ideas to expand in the UK market under the London mayor's India Emerging 20 (IE20) business programme. In the first stage around 300 ideas were shortlisted and presented in front of a panel consisting of UK government representatives, out of which Happay, was one to make it through the top 20.

The IITians will now receive support from Sadiq Khan, the mayor of London, to expand their business in the UK and will get to help in form of discounted tax rates, financial aid, and business advice.

Elated to make it in the top 20, Anshul says, "Few years back, Indian companies were seen as service providers and the indigenously created products were not deem fit for the global market and now, when an Indian company wants to expand globally they are looked at as ones who have worked in one of the most complex and vast markets."
Looking back at his struggle, he said, "When we started out the perception was that people who fail to get jobs opt for startups. It was really difficult to recruit good talent. For first few years Varun and I were the only employees at Happay." At present the company employees 280 people and clocks over 1 million transactions per month.

One of the biggest challenges as a FinTech in India, according to Rai is, "Indian banks have not migrated to cloud technology, while all the corporates have shifted to the same. There is a huge gap between requirement of the corporates and what the banks provide." He says that his only requirement form London Mayor's office would be "a progressive bank."

Source:TIMES OF INDIA-2nd July,2018

Friday, July 06, 2018

Copyright Practice and Procedure Literary Manual 2018

The copyright office had prepared guidelines for examination of copyright application in different categories of works, viz literary, artistic, musical, cinematograph film and sound recording works.

The manual reflects the general practices and procedures for registration of literary works.

It explains the process for examination of literary work application(s), documentation of ownership; provides guidelines on how to identify the originality of authorship, copyrightable subject matter and discusses the grounds on which a discrepancy letter may be issued.

This document does not cover every principle of copyright law, the practice and procedure set forth in the document do not in themselves have the force and effect of law.

Personality Of The Day - Frida Kahlo de Rivera